ORIGINAL ARTICLE

Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis

P W Fowlie¹, P G Davis²

¹ Department of Child Health University of Dundee and Tayside University Hospital Trust, Dundee, Scotland, UK
² Department of Paediatrics, Royal Women’s Hospital, Melbourne and Murdoch Children’s Research Institute, Melbourne, Victoria, Australia

Correspondence to:
Correspondence to:
Dr Davis
Royal Women’s Hospital, 132 Grattan St, Carlton, Victoria 3053, Australia; pgd{at}unimelb.edu.au

Background: Rates of long term morbidity remain unacceptably high in infants surviving after preterm birth. Prophylactic indomethacin has been shown to effectively reduce the rate of intraventricular haemorrhage in this group but there is the potential for unwanted side effects because of reduced organ perfusion.

Objective: To examine the effect of prophylactic indomethacin on mortality and short and long term morbidity of preterm infants.

Data sources: Medline (1966–2002), the Cochrane Controlled Trials Register and abstracts of the Society for Pediatric Research and the European Society for Pediatric Research were searched independently by both authors.

Review methods: Trials were included if they used a randomised design, enrolled preterm infants given intravenous indomethacin within 24 hours of birth, and reported any of the prespecified outcome measures. Each author extracted data and assessed trial quality independently, according to the methods of the Cochrane Collaboration. Data were combined in a meta-analysis where appropriate.

Results: Nineteen trials fulfilling the inclusion criteria were identified, of which four reported long term outcomes. Short term benefits of indomethacin were identified, including a reduction in the rate of severe intraventricular haemorrhage (relative risk (RR) 0.66 (95% confidence interval (CI) 0.53 to 0.82)) and the need for surgical ligation of a patent ductus arteriosus (RR 0.51 (95% CI 0.37 to 0.71)). No evidence of short term gastrointestinal or renal adverse effects was detected. There was no significant difference between indomethacin and control groups with respect to the important long term outcome of death or severe neurosensory impairment (RR 1.02 (95% CI 0.90 to 1.15)).

Conclusions: Prophylactic indomethacin has a number of short term benefits for the preterm infant but there is no evidence to suggest that it results in an improvement in the rate of survival free of disability.

Keywords: very low birth weight; neurodevelopment; patent ductus arteriosus; intraventricular haemorrhage

Abbreviations: IVH, intraventricular haemorrhage; PDA, patent ductus arteriosus; RR, relative risk; CI, confidence interval

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Fantoms

Ben Stenson
Arch. Dis. Child. Fetal Neonatal Ed. 2003 88: F448. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Laughon, M., Allred, E. N., Bose, C., O'Shea, T. M., Van Marter, L. J., Ehrenkranz, R. A., Leviton, A., for the ELGAN Study Investigators, (2009). Patterns of Respiratory Disease During the First 2 Postnatal Weeks in Extremely Premature Infants. Pediatrics 123: 1124-1131 [Abstract] [Full Text]  
• Bhandari, V., Zhou, G., Bizzarro, M. J., Buhimschi, C., Hussain, N., Gruen, J. R., Zhang, H. (2009). Genetic Contribution to Patent Ductus Arteriosus in the Premature Newborn. Pediatrics 123: 669-673 [Abstract] [Full Text]  
• Madan, J. C., Kendrick, D., Hagadorn, J. I., Frantz, I. D. III, the National Institute of Child Health and Human D, (2009). Patent Ductus Arteriosus Therapy: Impact on Neonatal and 18-Month Outcome. Pediatrics 123: 674-681 [Abstract] [Full Text]  
• Osborn, D. A., Evans, N., Kluckow, M., Bowen, J. R., Rieger, I. (2007). Low Superior Vena Cava Flow and Effect of Inotropes on Neurodevelopment to 3 Years in Preterm Infants. Pediatrics 120: 372-380 [Abstract] [Full Text]  
• Chorne, N., Leonard, C., Piecuch, R., Clyman, R. I. (2007). Patent Ductus Arteriosus and Its Treatment as Risk Factors for Neonatal and Neurodevelopmental Morbidity. Pediatrics 119: 1165-1174 [Abstract] [Full Text]  
• Back, S. A., Riddle, A., McClure, M. M. (2007). Maturation-Dependent Vulnerability of Perinatal White Matter in Premature Birth. Stroke 38: 724-730 [Abstract] [Full Text]  
• Miller, S. P., Mayer, E. E., Clyman, R. I., Glidden, D. V., Hamrick, S. E.G., Barkovich, A. J. (2006). Prolonged Indomethacin Exposure Is Associated With Decreased White Matter Injury Detected With Magnetic Resonance Imaging in Premature Newborns at 24 to 28 Weeks' Gestation at Birth. Pediatrics 117: 1626-1631 [Abstract] [Full Text]  
• Manzar, S. (2006). High-Dose Indomethacin for Patent Ductus Arteriosus Closure: How Strong Is the Evidence?. Pediatrics 117: 1863-1863 [Full Text]  
• Brooks, J M, Travadi, J N, Patole, S K, Doherty, D A, Simmer, K (2005). Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch. Dis. Child. Fetal Neonatal Ed. 90: F235-f239 [Abstract] [Full Text]  
• Choi, B. M., Lee, K. H., Eun, B. L., Yoo, K. H., Hong, Y. S., Son, C. S., Lee, J. W. (2005). Utility of Rapid B-Type Natriuretic Peptide Assay for Diagnosis of Symptomatic Patent Ductus Arteriosus in Preterm Infants. Pediatrics 115: e255-e261 [Abstract] [Full Text]